It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2014
  5. "QuickNavi Strep A" April 14 Market Launch in Japan Test Kit for the Rapid Detection of Group A Beta-hemolytic Streptococcal Antigen

April 1, 2014

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

"QuickNavi Strep A" April 14 Market Launch in Japan
Test Kit for the Rapid Detection of Group A Beta-hemolytic Streptococcal Antigen

  • Rapid (five minutes) and highly sensitive test for the detection of infection with group A beta-hemolytic Streptococcus - approximately 90 percent of positive infections can be detected within two minutes. Preparation of the test sample is a simple one-step process.
  • The main symptoms of group A Streptococcus infection are fever, pharyngitis, and tonsillitis. Group A Streptococcus infects individuals across a wide range of ages. It is a perennial bacteria, and circulates mainly in early spring and in winter.
  • The "QuickNavi" series of test kits is characterized by simple operation and rapid, sensitive detection capability, and the launch of QuickNavi Strep A adds group A Streptococcus, a rapid test kit for which has been in great demand, to the QuickNavi brand line.

Otsuka Pharmaceutical Co., Ltd. announced it will on April 14, 2014 in Japan launch the "QuickNavi Strep A" rapid test kit for beta-hemolytic group A Streptococcus. This will be the sixth diagnostic test kit in the "QuickNavi" series of kits, which are noted for their simple operation and rapid detection capability.

The "QuickNavi Strep A" kit is a device type kit with a detection line that is easy to see. Preparation of the test solution is a simple, one-step process, unlike with existing products. Children are the primary target population for testing, and the use of a flocked swab makes it easier to collect throat samples than a conventional cotton swab. Detection sensitivity is high, and detection is rapid - five minutes. Normally, approximately 90 percent of positive infections can be detected within two minutes.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases